This is a clean sweep for BSX, the patent is invalid and the product does not infringe. The case is over with no further appeal available to UT on the merits (the Federal Circuit reversed on both grounds). Traders should view this as a definitive removal of a multi-year litigation overhang. Monitor for any petition for certiorari to the Supreme Court, though the factual findings make that unlikely. No other near-term catalysts from this case.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $46.06entry
- T+1 · 4mo ago −0.04%α +1.50% · $46.04
- T+5 · 4mo ago +6.58%α +2.47% · $49.09
- T+20 · 3mo ago +8.25%α +4.87% · $49.86
- T+60 · 27d ago −3.37%α −7.72% · $44.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Federal Circuit reversed the district court's denial of JMOL and ruled in favor of Boston Scientific (BSX) on all counts in a patent infringement suit brought by the University of Texas (UT). The court held that UT's patent claims were invalid for anticipation by prior art (Song patent) and that BSX's drug-eluting stent coating does not infringe because it is not a 'thread-like' fiber. This eliminates a material liability risk that had been hanging over BSX since a jury verdict in 2024, removing the threat of a reasonable-royalty damages award and any potential injunction on its coronary stent product line.
Court Ruling Details
Key Facts
- Federal Circuit reversed the district court's denial of JMOL, finding BSX entitled to judgment as a matter of law on both anticipation and noninfringement.
- The court held that UT's '296 patent claims are invalid for anticipation by the prior-art Song patent, which teaches a biodegradable polymer fiber with immiscible phases and varying release rates.
- The court also held that BSX's accused stent coating is not a 'thread-like' fiber under the claim construction, so there is no infringement.
- The ruling eliminates the jury's finding of infringement and the reasonable-royalty damages award (amount not stated in the opinion), as well as any risk of an injunction on BSX's drug-eluting coronary stent systems.
- Costs were awarded to BSX as the appellant.
Financial Impact
Eliminates an unspecified reasonable-royalty damages award from the jury verdict and removes any risk of an injunction on BSX's drug-eluting coronary stent product line. The damages amount is not stated in the opinion.
Risk Factors
- UT could petition for certiorari to the Supreme Court, though the Federal Circuit's factual findings on anticipation and noninfringement make reversal unlikely.
- No damages amount was specified in the opinion, so the exact financial exposure eliminated is unknown but the risk of an injunction on a major product line was material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 court opinions.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2b05bbc35d-BSX |
| COURT-RULING Data (Synthetic) | court-bcc5a3f50e-BSX |
Track record
22 reports on BSX
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.
Filters
- Oct 28, 202619d ago 8-K Bearish 6/10 No price data
- Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
- Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
- Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
- Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
- Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
- Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers